Positions

Overview

  • Dr. Luckhardt completed her medical training in May 2000 from the Louisiana State University Health Sciences Center in Shreveport, Louisiana, where she graduated Alpha Omega Alpha. She completed her Internal Medicine training at the University of Iowa Hospitals and Clinics in 2003. She was Chief Resident of Internal Medicine at the University of Iowa from 2003-2004. She then completed her Pulmonary and Critical Care Training at the University of Michigan. She was appointed as faculty there from 2007 until 2009 when she joined the faculty at UAB. Dr. Luckhardt has also completed a Masters program at the University of Michigan in 2009 in Clinical Research Design and Biostatistics. She has served on the American Thoracic Society Training committee, and on the University of Michigan's Pulmonary Fellow's Education committee.

    Dr. Luckhardt has particular interests in evaluating and treating patients with interstitial lung disease. She is working to build collaborations with Rheumatology and Cardiology to treat patients with interstitial lung disease and in particular patients with connective tissue disease-associated ILD. Dr. Luckhardt is also the Medical Director of the inpatient Pulmonary services and the Specialty Care Unit and has interest in the management of patients with advanced lung disease and chronic respiratory failure.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO RegistryRespiratory Research.  23. 2022
    2022 Provider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung DiseaseChest.  162:375-384. 2022
    2022 Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis An Analysis of the IPF-PRO RegistryAnnals of the American Thoracic Society.  19:981-990. 2022
    2021 Hospitalizations in patients with idiopathic pulmonary fibrosisRespiratory Research.  22. 2021
    2021 Correlates of survival after autoantibody reduction therapy for acute IPF exacerbationsPLoS One.  16. 2021
    2021 Essential Components of an Interstitial Lung Disease Clinic: Results From a Delphi Survey and Patient Focus Group AnalysisChest.  159:1517-1530. 2021
    2021 A National Survey of Burnout and Depression Among Fellows Training in Pulmonary and Critical Care Medicine: A Special Report by the Association of Pulmonary and Critical Care Medicine Program DirectorsChest.  159:733-742. 2021
    2020 Associations between patient-reported outcomes and death or lung transplant in idiopathic pulmonary fibrosis data from the idiopathic pulmonary fibrosis prospective outcomes registryAnnals of the American Thoracic Society.  17:699-705. 2020
    2020 Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohortBMC Pulmonary Medicine.  20. 2020
    2020 The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosisRespiratory Medicine.  161. 2020
    2020 Updated evaluation of the safety, efficacy and tolerability of pirfenidone in the treatment of idiopathic pulmonary fibrosisDrug, Healthcare and Patient Safety.  12:85-94. 2020
    2019 Preoperative Evaluation of Patients With Interstitial Lung DiseaseChest.  156:826-833. 2019
    2019 Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patientsPLoS One.  14. 2019
    2019 Predicting outcome in idiopathic pulmonary fibrosis: Addition of fibrotic score at thin-section ct of the chest to gender, age, and physiology score improves the prediction model 2019
    2019 Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapiesAmerican Journal of Respiratory and Critical Care Medicine.  200:133-139. 2019
    2019 Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  200:199-208. 2019
    2017 Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung diseaseAging Cell.  16:1114-1124. 2017
    2017 Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort studyEuropean Respiratory Journal.  50. 2017
    2017 Measures of frailty in chronic lung diseasesAnnals of the American Thoracic Society.  14:1266-1267. 2017
    2017 Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-β 2017
    2017 Erratum: 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs (JCI Insight. (2017) 2:2 (e91377) DOI: 10.1172/jci.insight.91377)JCI Insight.  2. 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.JCI Insight.  2:e91377. 2017
    2017 What is in a pattern? that which we call idiopathic pulmonary fibrosis by any other pattern would behave alike!American Journal of Respiratory and Critical Care Medicine.  195:10-12. 2017
    2016 Alveolar epithelial disintegrity in pulmonary fibrosis 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survivalRespiratory Medicine.  115:33-38. 2016
    2016 Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where to Now?Drugs.  76:291-300. 2016
    2015 Systemic sclerosis-associated fibrosis: An accelerated aging phenotype?Current Opinion in Rheumatology.  27:571-576. 2015
    2014 Therapeutic targeting of Src kinase in myofibroblast differentiation and pulmonary fibrosisJournal of Pharmacology and Experimental Therapeutics.  351:87-95. 2014
    2014 NADPH oxidases in lung health and diseaseAntioxidants and Redox Signaling.  20:2838-2853. 2014
    2012 Neuronal Wiskott-Aldrich syndrome protein (N-WASP) is critical for formation of α-smooth muscle action filaments during myofibroblast differentiation 2012
    2012 Update in diffuse parenchymal lung disease 2011American Journal of Respiratory and Critical Care Medicine.  186:24-29. 2012
    2011 TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis 2011
    2011 New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosisDrugs.  71:981-1001. 2011
    2010 Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repairAmerican Journal of Respiratory and Critical Care Medicine.  182:1030-1037. 2010
    2010 Latent herpesvirus infection augments experimental pulmonary fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  181:465-477. 2010
    2009 NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injuryNature Medicine.  15:1077-1081. 2009

    Chapter

    Year Title Altmetric
    2010 Addictive Disorders in the Intensive Care Unit.  167-179. 2010

    Research Overview

  • To complement her clinical interest in interstitial lung disease, Dr. Luckhardt has undertaken basic and translational investigations into the pathogenesis of idiopathic pulmonary fibrosis. She is principal investigator and co-investigator on multiple industry sponsored clinical trials in IPF and CTD-ILD. She also has a grant from the Pulmonary Fibrosis Foundation to study frailty as an outcome measure for IPF.
  • Principal Investigator On

  • Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis  awarded by Pulmonary Fibrosis Foundation
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh The
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by PRIME EDUCATION LLC
  • Private Grant  awarded by GALAPAGOS NV.
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by CSL BEHRING, LLC
  • Private Grant  awarded by HORIZON THERAPEUTICS
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary FibrosiCleanUP-IPF  awarded by Weill (Joan and Sanford I.) Medical College of Cornell University
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh The
  • TLR9 Activation and Fibrotic Responses in Alveolar Epithelial Cells  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • UAB Interstitial Lung Disease Program  awarded by Pulmonary Fibrosis Foundation
  • Investigator On

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro)  awarded by Duke University
  • PAI-1 and Aging-Related Susceptibility to Lung Fibrosos  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by VERILOGUE, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by MALLINCKRODT ARD, INC
  • Private Grant  awarded by BIOGEN MA INC
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD
  • Private Grant  awarded by GENKYOTEX SA
  • Private Grant  awarded by RESPIVANT SCIENCES, GMBH
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by CHIMERIX, INC.
  • Private Grant  awarded by BELLEROPHON PULSE TECHNOLOGIES LLC
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by PURE TECH HEALTH LLC
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by KINEVANT SCIENCES INC
  • Private Grant  awarded by KINEVANT SCIENCES INC
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by ATYR PHARMA, INC.
  • Private Grant  awarded by THIRD POLE THERAPEUTICS
  • Private Grant  awarded by PURETECH LYT 100, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • Rituximab Therapy in Patients with IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by TULANE UNIVERSITY
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Core C: Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Teaching Overview

  • Dr. Luckhardt has served as a mentor for several fellows pursuing translational and outcomes based projects in interstitial lung disease.
  • Education And Training

  • University of Iowa Hospitals and Clinics, Internship
  • University of Iowa Hospitals and Clinics, Residency
  • University of Michigan Hospitals & Health Centers, Postdoctoral Fellowship
  • Doctor of Medicine, Louisiana State University System : Shreveport 2000
  • Full Name

  • Tracy Luckhardt